Jazz lifted by third EU approval for GW Pharma’s EpidyolexGW Pharmaceuticals’ Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for Share XJazz lifted by third EU approval for GW Pharma’s Epidyolexhttps://pharmaphorum.com/news/jazz-lifted-by-third-eu-approval-for-gw-pharmas-epidyolex/
Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW PharmaJazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed Share XJazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharmahttps://pharmaphorum.com/news/jazz-agrees-7-2bn-deal-to-buy-cannabis-meds-pathfinder-gw-pharma/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
De-busting the myths about medical cannabisMedical cannabis has quickly become the most socially disruptive phenomenon of the new millennium, and it is showing Share XDe-busting the myths about medical cannabishttps://pharmaphorum.com/r-d/views-analysis-r-d/de-busting-the-myths-about-medical-cannabis/
Addressing the medical cannabis knowledge gapThe legalisation of medical cannabis in November 2018 was hailed as a landmark victory for the British medical Share XAddressing the medical cannabis knowledge gaphttps://pharmaphorum.com/views-analysis-market-access/addressing-the-medical-cannabis-knowledge-gap/
Sandoz joins medical cannabis drive with Tilray dealNovartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a Share XSandoz joins medical cannabis drive with Tilray dealhttps://pharmaphorum.com/news/sandoz-joins-medical-cannabis-drive-with-tilray-deal/
Beckley Canopy Therapeutics raises £7.4m for cannabis R&DOxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the Share XBeckley Canopy Therapeutics raises £7.4m for cannabis R&Dhttps://pharmaphorum.com/news/beckley-canopy-therapeutics-raises-7-4m-for-cannabis-rd/
UK opens doors to cannabis-based therapies via NHSMedical cannabis is available to certain patients across the UK for the first time from today. The groundbreaking Share XUK opens doors to cannabis-based therapies via NHShttps://pharmaphorum.com/news/medicinal-cannabis-legal-nhs/
Review finds medical benefits of cannabis-based drugsThe use of medical cannabis in the UK has moved a step closer, after the home secretary asked Share XReview finds medical benefits of cannabis-based drugshttps://pharmaphorum.com/news/review-finds-medical-benefits-cannabis-drugs/
